Extracted the following table from The Edge Daily @ 21 October 2019.
Do a quick simple regression analysis on the above table – comparing the companies’ PE vs their ROE. It appears that Kotra is relatively undervalued if compared to its peers. APEX is about fairly valued as per the regression equation, whilst YSP / Pharmaniaga / Duopharma appear to be currently valued at higher than as per predicted by the regression equation.
DISCLAIMER: THIS IS A PERSONAL INVESTMENT BLOG AND SHALL NOT BE RELIED IN WHATSOEVER MANNER BY ANYONE. ALL ARTICLES CONTAINED IN THIS SITE ARE STRICTLY FOR INFORMATION, ENTERTAINMENT AND ILLUSTRATIVE PURPOSES ONLY AND DOES NOT PURPORT TO SHOW ACTUAL RESULTS. IT IS NOT, AND SHOULD NOT BE REGARDED AS INVESTMENT ADVICE OR AS A RECOMMENDATION REGARDING ANY PARTICULAR SECURITY OR COURSE OF ACTION. SOURCES USED IN THIS SITE HAVE NOT BEEN INDEPENDENTLY VERIFIED FOR ACCURACY, COMPLETENESS AND TIMELINESS. YOU SHOULD SEEK INDEPENDENT AND PROFESSIONAL INVESTMENT ADVICE IN REGARD TO YOUR INVESTMENT DECISIONS. THE AUTHOR MAY HOLD POSITIONS IN THE SECURITIES MENTIONED IN THE ARTICLES.